Loading organizations...
§ Private Profile · New York City, NY, USA
Helex is a technology company.
Helex develops genomic medicines specifically targeting renal indications, utilizing a proprietary approach that combines non-viral targeted delivery with advanced genome editing technologies. The company’s platform focuses on engineering genetic solutions for kidney diseases, leveraging CRISPR technology to enable precise and safer gene editing for therapeutic applications. This method seeks to overcome limitations of traditional gene therapies by offering targeted intervention directly to affected kidney cells.
The company was co-founded in 2021 by Rohini Kalvakuntla and Poulami Chaudhuri. Their foundational insight stemmed from recognizing the significant unmet medical need in kidney diseases and the potential of applying precise genomic editing, particularly non-viral targeted delivery, to this complex biological system. Their backgrounds in biotech and genomics informed the strategic decision to focus on this challenging therapeutic area.
Helex aims to serve patients suffering from high-burden kidney diseases, addressing populations where current treatments offer limited efficacy. The company’s long-term vision is centered on making advanced genomic therapies for renal conditions both accessible and affordable, thereby providing transformative options for individuals with chronic and acute kidney ailments and improving patient outcomes globally.
Helex has raised $5.0M across 2 funding rounds.
Helex has raised $5.0M in total across 2 funding rounds.
Helex has raised $5.0M in total across 2 funding rounds.
Helex's investors include Roopan Aulakh, SOSV, Sovereign Internet and Identity, Wilbur-Ellis [Cavallo], Roger Kuo, Dhruv Vohra, Sourav Gupta, BlueHill Capital.
Helex has raised $5.0M across 2 funding rounds. Most recently, it raised $4.0M Seed in October 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2025 | $4M Seed | Roopan Aulakh | SOSV, Sovereign Internet And Identity, Wilbur Ellis [cavallo], Roger KUO, Dhruv Vohra, Sourav Gupta, Bluehill Capital | Announced |
| Aug 1, 2021 | $1M Seed | — | SOSV, Sovereign Internet And Identity, Wilbur Ellis [cavallo], Roger KUO | Announced |
Helex is an early preclinical biotechnology company based in the US and India, focused on developing genomic medicines for high-burden kidney diseases, particularly genetic conditions like Autosomal Dominant Polycystic Kidney Disease (ADPKD).[2] It builds proprietary lipid nanoparticle delivery platforms and gene editing tools to enable targeted, non-viral therapies for over 700 million people worldwide affected by chronic kidney disease, addressing unmet needs through rational drug design, precise editing, and safety-focused innovations like avoiding off-target effects.[2] Helex serves patients with genetic kidney disorders, solving problems of limited treatment options by extending advanced therapeutics to the kidney via innovative delivery systems, with a mission to make therapies accessible and affordable.[2][5]
Helex emerged from a team of scientists with deep expertise in molecular biology, bioengineering, gene editing, and drug delivery, many holding PhDs from institutions like King’s College London, National Tsing Hua University, and IIT Delhi, alongside postdoctoral experience at places like TCS Innovation Labs, George Mason University, and Hebrew University.[5] The idea stems from identifying gaps in renal therapeutics, leveraging proprietary platforms for non-viral kidney-targeted delivery to unlock gene editing for diseases like ADPKD, building on the founders' backgrounds in peptide-mediated delivery, nanotechnology, and endocrinology.[2][5] Early traction focuses on preclinical development of a robust renal franchise, with the team's diverse academic and industry pedigrees—spanning India, UK, US, Taiwan, and Israel—driving its US-India operations.[2][5]
Helex rides the wave of gene editing and non-viral delivery advancements, capitalizing on trends like CRISPR evolution and lipid nanoparticles (proven in mRNA vaccines) to target hard-to-reach organs like the kidney.[2] Timing is ideal amid rising chronic kidney disease prevalence—driven by aging populations, diabetes, and hypertension—where genetic therapies remain underexplored despite 700 million cases globally, creating tailwinds from regulatory interest in precision medicine for rare diseases.[2] Market forces favoring Helex include biotech funding for platform technologies and partnerships in renal genomics, positioning it to influence the ecosystem by pioneering kidney-focused gene therapies and potentially accelerating trials for ADPKD and beyond.[2]
Helex is poised to advance its preclinical pipeline into clinical trials, likely prioritizing ADPKD candidates with its lipid nanoparticle platform, amid booming demand for renal gene therapies.[2] Trends like AI-optimized editing, expanded non-viral vectors, and global CKD awareness will shape its path, potentially drawing big pharma partnerships for scale-up and commercialization.[2] Its influence could grow by establishing kidney delivery as a new standard, evolving from early biotech to a renal franchise leader—transforming unmet needs into accessible genomic solutions, much like its founding mission to serve the underserved.[2][5]